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The pharmaceutical industry is faced with steadily declining R&D efficiency which results in fewer drugs
reaching the market despite increased investment. A major cause for this low efficiency is the failure of
drug candidates in late-stage development owing to safety issues or previously undiscovered side-effects.
We analyzed to what extent gene expression data can help to de-risk drug development in early phases
by detecting the biological effects of compounds across disease areas, targets and scaffolds. For eight drug
discovery projects within a global pharmaceutical company, gene expression data were informative and
able to support go/no-go decisions. Our studies show that gene expression profiling can detect adverse
effects of compounds, and is a valuable tool in early-stage drug discovery decision making.
Drug Discovery Today  Volume 00, Number 00  January 2015 PERSPECTIVEIntroduction
In today’s pharmaceutical industry, a relatively
small number of drugs are being approved,
whereas research expenses are increasing,
patents are expiring and governments and
health insurance companies are pushing for low-
cost medications [1]. This situation is exacer-
bated by an average of 10% of marketed drugs
being withdrawn from the market at some stage
or requiring black box warnings because of
adverse biological effects and failures in clinical
Phase III and after. FDA submission failures have
increased to 50% in recent years [2]. In addition
to health risks for clinical trial participants, late
failures are extremely costly because large
amounts of time and capital have already beenPlease cite this article in press as: Hochreiter, S. Using transcri
(2015), http://dx.doi.org/10.1016/j.drudis.2014.12.014
1359-6446/ 2015 The Authors. Published by Elsevier Ltd. This is an o
http://dx.doi.org/10.1016/j.drudis.2014.12.014 invested in developing the drug. Depending on
the assumptions made, the development of a
new drug costs in the order of US$1 billion and
takes the best part of a decade to reach the
market [3,4].
Accordingly, the ‘Holy Grail’ of drug develop-
ment is to identify future failures early – even
before they enter clinical phases – and thereby
save significant expenditures later on. In phar-
maceutical drug discovery the correct go/no-go
decisions must be made during all phases; how-
ever, decisions are particularly crucial during lead
optimization, because they determine which
compounds will enter costly preclinical and clin-
ical development [5,6] (Table 1). These decisions
should ideally be based on scientific parametersptomics to guide lead optimization in drug discovery projects: Le
pen access article under the CC BY-NC-ND license (http://creativecommothat are predictive of later outcomes and can be
measured quickly and cost-effectively.
To make decisions on a scientific basis,
researchers in the pharmaceutical industry are
now using a range of technologies for measuring
the biological effects of compounds. These
technologies are generally related either to ef-
ficacy, such as early-stage measuring of com-
pound–target interactions or animal-based
readouts in later stages, or to the detection of
adverse effects, such as safety profiling [7,8] or
more-complex biological readouts. The assays
used can capture either single biological effects
– the inhibition of a certain enzyme for instance
– or multiple biological effects, such as mRNA-,
protein- and imaging-based techniques [9–11].ssons learned from the QSTAR project, Drug Discov Today
ns.org/licenses/by-nc-nd/4.0/).
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TABLE 1
Typical decision points in drug discovery projects and the type of decision to be taken in each step
Decision point Important criteria for decision Decision support available
Choice of disease Patient need; commercial aspects Statistics on disease distributions; input from practitioners
Target selection ‘Validated’ target (i.e. involved in disease
modulation and druggable)
Biological studies (e.g. knockdown experiments, genetic
linkages); chemical biology/probes
Screening library assembly Chemistry with no obvious liabilities, ease of
synthesis of analogs, good assumed or proven
PK/PD properties
Chemoinformatics analysis of chemical space; historical hit
distributions in chemical space
Assay development Predictivity; reproducibility; throughput; price Experience of biologists
Screening/hit list triaging Data quality; increasing certainty about true and
false positives and negatives
Experience of screeners/follow-up scientists
Lead optimization On-target and off-target activities; favorable drug
metabolism and pharmacological properties
Biochemical and more-complex assay systems; gene
expression arrays
Preclinical studies Efficacy and side-effect profile Animal experiments
Clinical studies Efficacy and side-effect profile Testing of drug candidate in large (or stratified) cohorts
Approval Efficacy and side effect profile Results from preclinical and clinical studies
Marketing Market structure in disease area; comparative
advantage of drug with competitors in the market
Commercial information systems
This list is incomplete, but it illustrates the large number of multidimensional choices to be made during a typical project, most of which are go/no-go decisions between either two or
several (or even very many) options. In this work, we are particularly interested in supporting decisions in the lead optimization stage using gene expression data.
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activities of a compound in a living system into
account and provide data that convey more
information about its properties [10]. A multi-
dimensional assay that measured a wide diver-
sity of biological effects during lead optimization
would be highly desirable for making the right
decisions exceptionally early in the drug devel-
opment process and would save considerable
amounts of time and money. However, the ap-
plicability of these biotechnologies for the
evaluation of compound efficacy and safety in
real drug development projects is still to be
demonstrated.
One of the multidimensional assays that has
gained considerable attention in the past decade
is gene expression profiling. This technique si-
multaneously measures many of the biological
effects of a compound on the transcriptional level,
and thereby gives a comprehensive snapshot of
the biological state of a living system [12–14].
Transcriptomic changes following compound
administration can now also be measured in high
throughput, enabling screening of many com-
pounds in multiple cell lines at low cost. The use of
transcriptomic data for characterizing biological
effects of small molecules has become increas-
ingly popular since the advent of the Connectivity
Map [15]. Several applications ranging from
pathway elucidation [16], toxicity models [17,18]
and toxicogenomic classifications [19] to tool
discovery and drug repurposing [20–23] have
been developed based on drug-induced gene
expression profiling [9]. However, whereas these
studies certainly have significant scientific value,Please cite this article in press as: Hochreiter, S. Using transcri
(2015), http://dx.doi.org/10.1016/j.drudis.2014.12.014
2 www.drugdiscoverytoday.comthey do not address the utility of gene expression
profiling for decision making during the lead
optimization phase of a typical drug discovery
project. The objective of this phase is first to
prioritize a few chemotypes from previous phases
and then to optimize these lead compounds into
their desired bioactivity profiles as well as ADME–
Tox properties. This is very different from the
repurposing applications of Connectivity Map, in
which compounds are selected from a library with
broad functional and structural diversity. During
lead optimization a very narrow chemical space is
being considered, and more-fine-grained deci-
sions need to be made. The studies cited above
did not consider transcriptional profiles at the
level of resolution required for their use in the lead
optimization phase – a deficiency that our work
aims to address.
Few findings have been published on how
gene expression facilitates go/no-go decisions
during lead optimization. In one example, Fanton
et al. [24] found that gene expression data help in
the optimization of closely chemically related
compounds. However, this study focused solely
on on-target effects, whereas in lead optimization
the detection of off-target effects is crucial. Baum
et al. [25] investigated off-target effects and were
able to prioritize compounds based on tran-
scriptional profiles; however, only a small number
of compounds from a single project were con-
sidered. This is insufficient for assessing the utility
of transcriptomic data for decision making in
early-stage pharmaceutical drug discovery.
We have now evaluated the utility of gene
expression profiling in eight drug discoveryptomics to guide lead optimization in drug discovery projects: Leprojects, named according to their biomolecular
target: fibroblast growth factor receptor (FGFR),
epidermal growth factor receptor (EGFR), ROS1,
hepatitis B virus (HBV), mGluR2PAM, phospho-
diesterase (PDE)10A, PDE4 and microsomal tri-
glyceride transfer protein (MTP); across four
disease areas: oncology, virology, neuroscience
and metabolic diseases. The experiments were
performed from 2010 to 2013 at Janssen Re-
search and Development, as part of the Quan-
titative Structure Transcriptional Activity
Relationships (QSTAR) Project [26]. We measured
the transcriptional effects of 757 compounds on
eight cell lines using a total of 1600 microarrays
developed by Affymetrix. On the basis of these
experiences, we found gene expression profiling
to be a highly valuable tool for lead optimization
in pharmaceutical discovery projects.
Results
Table 2 provides an overview of the projects and
disease areas that were explored in this study
with regard to the utility of using transcriptomic
data (measured by microarrays) in the lead op-
timization phase of pharmaceutical drug dis-
covery projects. Transcriptomic data provided
relevant information for six of the eight projects.
For three of them (ROS1, EGFR and PDE10A) the
data provided clear go/no-go decisions. In three
other projects (FGFR, mGluR2PAM and MTP)
transcriptomics delivered novel biological
insights but did not provide direct decision
support. In the remaining two cases (HBV and
PDE4) neither biological insights nor go/no-go
decisions were gained. Four projects aressons learned from the QSTAR project, Drug Discov Today
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TABLE 2
Overview of the pharmaceutical projects included in the QSTAR project for which transcriptomic profiling was performed
Target Therapeutic area Result Utility Decision
ROS1 Oncology Selectivity and on-target Useful No-go for certain chemotypes
EGFR Oncology On-target and off-target Useful No-go and go for certain compounds
PDE10A Neuroscience Off-target Useful No-go for certain compounds
MTP Metabolic On-target (inconsistency with assay data) Relevant
mGluR2PAM Neuroscience Off-target (further exploration needed) Relevant
FGFR Oncology On-target (no differentiation among compounds) Relevant
HBV Virology Limited GE effects No added value
PDE4 Neuroscience Limited GE effects No added value
Abbreviations: EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; GE, Gene expression; HBV, hepatitis B virus; MTP, microsomal triglyceride transfer protein;
PDE, phosphodiesterase; QSTAR, quantitative structure transcriptional activity relationships; ROS1, Proto-oncogene tyrosine-protein kinase ROS.
The columns give the biomolecular target, the therapeutic area, the result of the gene expression data analysis, the utility for the drug design process and how this source of information
contributed to decision making. All projects are described in more detail in the text (see also Supplementary material online).
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are described in Supplementary material.
PDE10A project
In this project, the aim was to develop com-
pounds inhibiting PDE10A which is almost ex-
clusively expressed in the striatum and is
considered as a novel therapeutic avenue in the
discovery of antipsychotics [27]. Although the
efficacy of the investigated compounds was
high, adverse effects emerged as a point of
concern. Therefore, the compounds were pro-
filed with respect to their induced gene ex-
pression on HEK293 cells transfected with the
mouse homolog of PDE10A. Three compounds
strongly downregulated the expression of tu-
bulin genes (Fig. 1b), which was the strongest
transcriptional module observed (Fig. 1c) in this
experiment. Downregulation of tubulin genes
suggests a possible genotoxic effect on the
microtubule-based chromosome segregation
(Fig. 1a). Hence the compounds were profiled in
a micronucleus test (MNT) [28] – a genotoxicity
test for detecting micronuclei in the cytoplasm
of interphase cells. The micronuclei formation
for one of the three compounds showing tu-
bulin downregulation is presented in Fig. 1d.
The tubulin downregulation was strongly cor-
related with highly positive MNT scores (a 20.6-
fold to 28.1-fold increase in micronuclei for-
mation). By contrast, structurally similar com-
pounds with nonsignificant tubulin
downregulation did not show an influence on
micronucleus formation.
The tubulin genes were used in a next step as
a gene signature to query the Connectivity Map
[15,29]. The top five ranked compounds re-
trieved with this signature were mebendazole
(two instances), chelidonine, vinblastine and
nocodazole. Vinblastine is a known reference
compound used in MNT assays as a positivePlease cite this article in press as: Hochreiter, S. Using transcri
(2015), http://dx.doi.org/10.1016/j.drudis.2014.12.014control for the induction of MN formation [30].
Mebendazole and nocodazole are both benzi-
midazoles that are also considered model
compounds for demonstrating thresholded
responses of aneugenic compounds [31]. Hence,
our identification of MNT-positive compounds
using gene expression signatures could also be
validated on external data. In a subsequent
transcriptional profiling experiment, nocodazole
was also profiled, and the link between tubulin
genes and a positive MNT could be confirmed
(Fig. S1 in Supplementary material online).
The results from the PDE10A project clearly
show that transcriptomic profiling can identify
potentially genotoxic compounds in an early
phase of drug development. This is of practical
utility, given that in the standard drug discovery
pipeline in vitro pharmacological profiling for the
formation of micronuclei is usually applied at a
rather late stage. The tubulin gene expression
signature, however, allows identification of mi-
cronucleus formation much earlier and, thereby,
prevents failure of selected compounds owing to
this effect at later stages.
EGFR project
Our second project was an oncology project,
focusing on inhibition of EGFR [32]. Given in-
creasing resistance to current EGFR inhibitors
(gefitinib and erlotinib) [33], there is still a need
for novel therapies. Compounds with a macro-
cycle structure were derived from the two ref-
erence compounds (Fig. 2c) and synthesized.
Thirty-five of them were selected for transcrip-
tomic profiling to identify compounds with
similar biological effects to the reference com-
pounds. A compound-induced transcriptional
module was discovered (see supplementary
material online) in which some genes were
downregulated for the two reference com-
pounds as well as five macrocycle compoundsptomics to guide lead optimization in drug discovery projects: Le(Fig. 2a). The most significant gene of this
module encodes the fibroblast growth factor
carrier protein (FGFBP1) the expression of which
is downregulated via the mitogen-activated
protein kinase/extracellular signal-related kinase
(MAPK/ERK) pathway after EGF-stimulated inhi-
bition of EGFR [34]. Also, several other genes of
the module, such as FOSL1, are located down-
stream of the MAPK/ERK pathway [35].
We confirmed that this transcriptional effect
induced by the compounds and gefitinib and
erlotinib is related to the inhibition of the pro-
liferation of cancer cells by an assay measuring
cell growth: FGFBP1 downregulation is indeed
highly negatively correlated with the prolifera-
tion assay (Fig. 2c). Additionally, we were able to
link cell growth activity and FGFBP1 downregu-
lation to a particular chemical feature (Fig. 2c,d),
which was detrimental to biological activity and,
in turn, probably also to the efficacy of the
compound. One of the five active macrocycles
could be deprioritized based on a potential
severe off-target effect discovered solely using
transcriptomics data. In the case of this com-
pound, mitochondrial membrane genes like
MT1X were found to be downregulated, which
might hint to a failure at later phases [36]
(Fig. 2b). This resulted in a clear no-go decision
for further development for this compound. This
example demonstrates the use of gene expres-
sion profiling as a tool to confirm the desired
effect and to obtain insight into the mechanism
of action. Because transcriptomics experiments
allow the discovery of adverse effects, one of the
active compounds could be additionally
deprioritized based on a specific transcriptional
effect.
MTP project
The goal of the project was to develop com-
pounds that modulate MTP, which alters thessons learned from the QSTAR project, Drug Discov Today
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FIGURE 1
(a) Schematic representation of micronucleus formation during mitosis. Genotoxic compounds can either cause chromosomal breaks (clastogen) or affect the
formation of the mitotic spindle or microtubule (aneugen). (b) Gene profile plot of a transcriptional module detected in the phosphodiesterase (PDE)10A project.
Each row displays the standardized expression values of a gene across the compounds (along the x-axis). DMSO denotes controls for which only the compound
carrier DMSO was administered. Gray horizontal bars indicate the range of variation in DMSO controls. The distribution of the raw expression values is given on the
right by a violin plot for each gene. The transcriptional module found in the gene expression profiles of target compounds contains tubulin genes that are
downregulated by some compounds (colored green). (c) Volcano plot of the gene expression data of one compound showing clear downregulation of TUBB
genes. The fold change for each gene against the controls (x-axis) is plotted against its negative log P-value (y-axis). The P-value is computed by LIMMA with the
null hypothesis that a gene is not differentially expressed. The most significant differentially expressed genes against DMSO are placed in the upper left and right
corners. The tubulin genes are most significantly differentially expressed for this particular compound. (d) Microscopic and FACScan analysis demonstrating clear
MN-formation (yellow arrows) and G1 cell cycle arrest similar to the aneugenic reference compound, vinblastine. The compounds downregulating tubulin genes
(marked green in (b)) all have such an effect on the microtubule-based chromosome segregation.
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the cholesterol biosynthesis pathway [39]. Ke-
toconazole, an antifungal agent that blocks cy-
tochrome P450 14-alpha-demethylase (P450-
14DM), has multiple biomolecular targets and is
known to reduce cholesterol levels [40]. Struc-
tural derivatives of ketoconazole were synthe-
sized as potential MTP inhibitors, although lead
optimization of compounds with multiple un-
known targets is challenging with traditional
biochemical assays. Therefore, the compounds
were profiled using gene expression on multiple
cell lines: LnCap (human prostate cancer), HepG2
(human liver carcinoma) and SK-N-BE(2) (humanPlease cite this article in press as: Hochreiter, S. Using transcri
(2015), http://dx.doi.org/10.1016/j.drudis.2014.12.014
4 www.drugdiscoverytoday.combrain cancer). A transcriptional module con-
taining ten downregulated genes that belong to
the sterol regulatory element binding protein
(SREBP) cholesterol metabolism pathway was
detected in LnCap and HepG2 cells (Fig. 3a,b) but
not in SK-N-BE(2). Given the downregulation of
these genes, we reasoned that the inhibition of
MTP increases the cholesterol concentration in
the endoplasmatic reticulum [41,42], which is
detected by the SREBP cleavage activating
protein (SCAP). Owing to the high level of cho-
lesterol, SCAP cannot activate SREBP [43,44], and
thus the cholesterol biosynthesis pathway is
downregulated as desired. However, the rankingptomics to guide lead optimization in drug discovery projects: Leof the compounds based on the gene expression
patterns of the SREBP pathway genes is different
between the two cell lines (Fig. 3c), and it only
partially correlates with the cellular assays
measuring MTP inhibition (see Supplementary
material online). Owing to this inconsistency,
other transcriptional modules were not further
investigated. Although transcriptomic effects
related to the expected metabolic pathway are
observed in this project, further investigation
and exploitation are required before a decision
can be made; however, we did acquire
biological insights into the mode of action of
the compounds.ssons learned from the QSTAR project, Drug Discov Today
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FIGURE 2
(a) Gene profile plot of a transcriptional module detected in the epidermal growth factor receptor (EGFR) project. Each row displays the standardized expression
values of a gene across the compounds (along the x-axis). DMSO denotes controls for which only the compound carrier DMSO was administered. The distribution
of the raw expression values for each gene of the module is given on the right by a violin plot. The transcriptional module includes genes where expression is
downregulated in cells treated with the two reference compounds (gefitinib and erlotinib) and in five macrocycle compounds (green). The genes were shown to
be related to the on-target activity, the inhibition of EGFR. (b) Gene profile plot of another transcriptional module showing that one of the target-active
compounds has an off-target effect (marked by a purple ring). (c) Scatter plot of bioassay activity values (x-axis, expressed in pIC50) versus FGFBP1 gene expression
values (y-axis). A strong negative correlation is observed. The compounds that show a clear downregulation of FGFBP1 are colored in green. Furthermore, the
presence (red ring) or absence (gray ring) of a particular chemical feature is depicted. If the chemical feature is present then the FGFBP1 expression is high resulting
in a low bioassay activity. (d) Chemical structures of the two reference compounds gefitinib and erlotinib, together with two representatives of the macrocycle
compounds. A chemical feature, the oxygen in the ortho position of the aniline (highlighted in red), was found to reduce the activity of the compounds.
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EROS1 project
This project sought to develop compounds that
inhibit the proto-oncogene tyrosine protein ki-
nase ROS (ROS1). The ROS1 gene is overex-
pressed in several cancer types [45,46]. Lack of
selectivity was a particular concern given the
historical precedent for compounds of this tar-
get class [47]. Five chemotypes (A–E) had been
identified from the cellular screen for target
inhibition. We used the number of gene ex-Please cite this article in press as: Hochreiter, S. Using transcri
(2015), http://dx.doi.org/10.1016/j.drudis.2014.12.014pression changes induced by a given compound
as a measure of the selectivity of that compound.
This analysis clearly identified chemotype A as
the most selective (i.e. least effects on gene
expression; Fig. 4a), which was selected for
continued development. At the same time, no-
go decisions were made on the other chemo-
types (B–E).
In an attempt to improve the inhibitory ac-
tivity of compounds of chemotype A, 100ptomics to guide lead optimization in drug discovery projects: Leanalogs were synthesized. Cellular assays for
target inhibition indeed identified compounds
with high inhibitory activity among the analogs
of chemotype A. Our gene expression analysis
showed that there was no loss of the desirable
selectivity for even the most active analogs.
These drug candidates were thus promoted to
further preclinical development (Fig. 4b). This
example demonstrates the use of gene expres-
sion profiling to complement a focused cellularssons learned from the QSTAR project, Drug Discov Today
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FIGURE 3
(a) Gene profile plot of a transcriptional module detected in the HepG2 cell line of the microsomal triglyceride transfer protein (MTP) project. Each row displays the
standardized expression values of a gene across the compounds (along the x-axis). DMSO denotes controls for which only the compound carrier DMSO was
administered. Gray horizontal bars indicate the range of variation in DMSO controls. The distribution of the raw expression values is given on the right by a violin
plot for each gene. The module includes the genes HMGCS1, IDI1, FDFT1 and DHCR7 which encode proteins that belong to the sterol regulatory element binding
protein (SREBP) pathway (red box). Three compounds (green) are transcriptionally active on this gene module. (b) Gene profile plot of a transcriptional module
detected in the LnCap cell line of the MTP project. The same set of genes belonging to the SREBP cholesterol metabolism pathway was retrieved (red box). (c)
Scatter plot of the gene expression values of IDI1 in the HepG2 (x-axis) and in the LnCap cell line (y-axis) for each of the compounds (represented by dots). While
using the HepG2 cell line, three compounds (colored green) show a clear downregulation, these three compounds and some others are downregulated in the
LnCap cell line. (d) Pathway diagram of the SREBP pathway. The proteins corresponding to genes that are present in the transcriptional modules of HepG2 and
LnCap are marked by a red box.
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Eassay during compound selection and the
qualification of individual compounds for further
optimization.
Discussion
Assessing the utility of transcriptomic data for
decision making in early-stage pharmaceutical
drug discovery is rather challenging. The drug
discovery process spans a long time period,Please cite this article in press as: Hochreiter, S. Using transcri
(2015), http://dx.doi.org/10.1016/j.drudis.2014.12.014
6 www.drugdiscoverytoday.comtypically more than ten years. Hence, the impact
of decisions made during the QSTAR project
cannot be fully demonstrated because many
projects are still ongoing. These limitations are
inherently linked to such an assessment exercise.
However, given the examples, it is shown that
transcriptional profiling experiments can con-
tribute to decision making during the lead op-
timization phase of drug discovery projects. Theptomics to guide lead optimization in drug discovery projects: Lemultidimensional data generated from tran-
scriptomics experiments are ‘richer’ than con-
ventional assays based on single readouts. They
allow discovery of multiple patterns within the
same experiment that relate to different char-
acteristics of the compounds under investiga-
tion. Besides identifying interesting
transcriptional effects, project-relevant informa-
tion can also be gathered by quantifying thessons learned from the QSTAR project, Drug Discov Today
Drug Discovery Today  Volume 00, Number 00  January 2015 PERSPECTIVE
DRUDIS-1559; No of Pages 9
2
5
10
20
50
100
Compounds
N
um
be
r o
f i
nd
uc
ed
 tr
an
sc
rip
tio
na
l c
ha
ng
es
Chemotype
A
B
C
D
E
2
5
10
20
50
100
Compounds
5
6
7
8
Activity
5
6
7
8
Activity
N
um
be
r o
f i
nd
uc
ed
 tr
an
sc
rip
tio
na
l c
ha
ng
es
Drug Discovery Today 
FIGURE 4
Chemotype selection in the ROS1 project: chemotypes A, B, C, D and E are shown in pink, brown, green, blue and purple, respectively. (a) Bar plot showing the
number of genes with an absolute log fold change greater than 1 compared with the controls for each of the compounds in the initial set. The white spaces
indicate compounds for which no genes had an absolute log fold change greater than 1. The compounds are ordered within a chemotype according to their
inhibitory activity (represented by dots, expressed in pIC50). Compounds of chemotype A show the least number of transcriptional effects, but also on average
lower activity profiles. (b) Bar plot showing the number of genes with an absolute log fold change greater than 1 compared with the controls for each of the
compounds in the extended compound set of the ROS1 project. Additional compounds in chemotype A were added. Compounds are ordered again based on
pIC50 within chemotypes.
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Etranscriptional changes on an absolute scale. A
compound was defined as being ‘selective’ when
the number of differentially expressed genes
after compound administration is low compared
with other compounds within the same project.
Additionally, it is shown in the EGFR project that
transcriptomics data can be integrated in more
classical SAR modeling exercises.
Although transcriptomics data have been
shown to support decision making in a number
of projects, they also have their limitations.
Conceptually, transcriptional profiling is limited
in its nature because it cannot detect changes at
the metabolite or protein level. There could be
compounds that affect the function of a pathway
which is not reflected by a transcriptional
change. In general, from the data presented in
this work, higher numbers of transcriptional
effects were observed in oncology projects. A
plausible explanation is that the antiproliferative
activity of these compounds typically affects
many biological processes that are linked with
transcriptional changes.
We are not yet at a stage where we can easily
annotate the majority of transcriptional
responses and have assays readily available to
check the validity of each observation. As a
consequence, we could create data on candidate
drugs that are not yet interpretable but might
prove beneficial in their ongoing development.
This emphasizes the exploratory nature of
transcriptomics experiments. It enables the
generation of interesting hypotheses early but
important decisions could require validation in
follow-up experiments.Please cite this article in press as: Hochreiter, S. Using transcri
(2015), http://dx.doi.org/10.1016/j.drudis.2014.12.014As with all cell-based assays, the amount of
information that can be gained from transcrip-
tomic profiling depends on the type of cell line.
For detection of transcriptional effects related to
the desired activity, cell lines expressing the
target are suggested, whereas some adverse
effects might only be observable in other cell
lines. Besides cell line dependency, investigation
of compound-induced effects can be heavily
dose- and time-dependent. All compounds
within a certain project are profiled in equimolar
conditions to assess the differences in efficacy.
However, when the potencies between the
compounds within a project are diverse, some
compounds are too dilute to show effects. These
dependencies illustrate that an optimization of
the parameters (cell line, concentration and
administration time) before profiling is needed
to maximize the information that can be gained
from transcriptomic data. However, such an
optimization is only affordable when gene ex-
pression profiling technologies become even
less costly and more suitable for higher
throughput like the L1000 platform [48]. In the
other direction, high throughput RNA sequenc-
ing (RNA-Seq) enables more in-depth analysis of
transcriptional changes at a higher cost. The
transcriptomic data described in this paper were
all generated using microarray gene expression
chips, but the concepts, approaches and con-
clusions can be directly transferred to platforms
such as L1000 and RNA-Seq [49].
The overall conclusion of QSTAR is that tran-
scriptomic data typically detect biologically rel-
evant signals and are often able to help prioritizeptomics to guide lead optimization in drug discovery projects: Lecompounds beyond conventional target-based
assays. Most value is added to the decision
making process by warning signals that flag off-
target effects early on. Because gene expression
profiling is nowadays an affordable and fast
technique, in particular when compared with
other assays, it has the potential to be included
as a standard method early in the drug devel-
opment process to detect such off-target effects.
We expect that in the future the applicability of
transcriptional profiling will increase further
owing to continuous investments in the anno-
tation of transcriptional responses.
Materials and methods
For each project, gene expression data were
initially obtained for a small set of candidate
compounds, reference compounds (e.g. FDA-
approved drugs), target-active representatives of
candidate chemotypes and controls in a cell
system and at equimolar concentration and
treatment duration recommended by the re-
spective Janssen project teams. In some cases,
the set of compounds was extended with
structural analogs that were synthesized fol-
lowing certain decision points (see Supple-
mentary material online). The mRNA expression
data were quantile normalized, summarized [13]
and filtered [50,51]. Subsequent exploratory
analysis to detect strong transcriptomic effects
was performed using spectral map analysis [52].
Differentially expressed genes [53] were called
and transcriptional modules [54] (i.e. genes
where expression is simultaneously up- or down-
regulated in a subset of samples) were identifiedssons learned from the QSTAR project, Drug Discov Today
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(FABIA) method [55]. Transcriptional modules
related to the desired effect were identified by
the potential support vector machine (PSVM)
using target-related bioassay measurements
[56]. A data framework and analysis pipeline was
constructed to facilitate integrated analysis of
gene expression data, chemical structures and
bioassay results (see Supplementary material
online).
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